Highnoon Laboratories Limited Stock

Equities

HINOON

PK0070701013

Pharmaceuticals

End-of-day quote Pakistan S.E. 18:00:00 2024-07-14 EDT 5-day change 1st Jan Change
710 PKR +0.73% Intraday chart for Highnoon Laboratories Limited +1.22% +40.71%

Financials

Sales 2022 15.82B 56.84M 77.88M Sales 2023 19.77B 71.04M 97.33M Capitalization 26.73B 96.08M 132M
Net income 2022 2.47B 8.89M 12.18M Net income 2023 2.45B 8.8M 12.05M EV / Sales 2022 1.38 x
Net cash position 2022 838M 3.01M 4.13M Net cash position 2023 878M 3.16M 4.32M EV / Sales 2023 1.31 x
P/E ratio 2022
9.15 x
P/E ratio 2023
10.9 x
Employees 2,295
Yield 2022
3.7%
Yield 2023
5.95%
Free-Float 48.45%
More Fundamentals * Assessed data
Dynamic Chart
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Highnoon Laboratories Limited Announces Director Changes, Effective February 24, 2023 CI
Highnoon Laboratories Limited Announces Executive Changes CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Highnoon Laboratories Limited Appoints Adeel Abbas Haider as Chief Executive Officer CI
Highnoon Laboratories Limited Appoints Tauseef Ahmad Khan as Chairman CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
More news
1 day+0.73%
1 week+1.22%
Current month-0.50%
1 month-2.08%
3 months+25.36%
6 months+42.57%
Current year+40.71%
More quotes
1 week
699.99
Extreme 699.99
723.00
1 month
660.05
Extreme 660.05
739.90
Current year
465.50
Extreme 465.5
745.00
1 year
330.00
Extreme 330
745.00
3 years
322.10
Extreme 322.1
745.00
5 years
130.66
Extreme 130.6634
745.00
10 years
51.57
Extreme 51.5734
745.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 20-03-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 23-02-23
Chairman - 83-12-31
Director/Board Member - 88-02-29
More insiders
Date Price Change Volume
24-07-15 710 +0.73% 1,994
24-07-12 704.8 -0.60% 1,562
24-07-11 709.1 +1.30% 4,961
24-07-10 700 -1.68% 22,123
24-07-09 711.9 +1.49% 2,581

End-of-day quote Pakistan S.E., July 14, 2024

More quotes
Highnoon Laboratories Limited is a Pakistan-based company that is engaged in the manufacturing, importing, selling, and marketing of pharmaceutical and related consumer products. Its product categories include cardiology, metabolic, gastroenterology, musculoskeletal, anti-infective, obstetrics and gynecology, pediatrics, allergy, respiratory, and urology. Its cardiology products include Cuziper, Hitica, Apiban, Misar, and Herbesser. Its metabolic products include Daploz, Tagip, Diajard, and Nylomet. Its gastroenterology products include Rabecid, Racedo, Skilax, and Fosbu. Its musculoskeletal products include Kydor, Hilin, Airtal, and Tamadol. Its anti-infective products include Evacef, Maxum, Efix, and Cefia. Its obstetrics and gynecology product include Hitase. Its pediatrics product include Tres Orix Forte. Its allergy products include Leviva and Kestine. Its respiratory products include Combivair Forte, Glynvair, Betatec, Ultivair, and Montit. Its urology product include Prostam.
More about the company
  1. Stock Market
  2. Equities
  3. HINOON Stock